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Abstract— A new synthetic approach towards 1-alkoxy-2-aminoimidazolines that uses N-alkoxy-N-(2-aminoethyl)-2-
nitrobenzenesulfonamides as nucleophile reagents for the reaction with isothiocyanates is reported. Hence, the synthesis of 1-alkoxy-2-
aminoimidazolines was performed in high yield with a one pot procedure involving thiourea formation, nosyl group removal and 
spontaneous cyclization (42–77% overall yield).  
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 Our continuous effort in the search of new 
antitrypanosomal agents potentially useful against T. brucei 
rhodesiense,
1-3
 the protozoan parasite responsible for the 
acute form of sleeping sickness in sub-saharian Africa, led 
us to envisage the synthesis of compounds bearing 1-
alkoxy-2-aminoimidazolyl groups as potential prodrugs for 
the 2-aminoimidazoline cation. We previously showed that 
the ip administration of a bis(2-aminoimidazoline) 
derivative was able to cure two models of acute infection in 
mice i.e., T. b. brucei STIB 795 and T. b. rhodesiense 
STIB900.
3
  However, our lead compound (X = NH, Chart 
1) could not cure the late stage disease (i.e., with CNS 
involvement) probably due to a poor blood brain barrier 
(BBB) penetration caused by its dicationic nature.  
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In fact, this kind of guanidine compounds has very basic 
nitrogen atoms  (pKa = 9.9 for our lead compound)
4
 that 
are charged at physiological pH and as such potentially 
poorly liposoluble, leading to poor diffusion across the 
BBB. 
 Among the existing strategies to improve the 
pharmacokinetics of cationic compounds such as amidines 
or guanidines, the substitution of the basic N-atom with 
hydroxyl (or alkoxy group) or ester groups, affording less 
basic molecules that are not protonated at physiological pH, 
has been successfully applied to antimicrobials. In 
particular, the amidoxime prodrug strategy developed by 
Clement and co-workers
5
 and used by the group of Boykin 
and Tidwell to improve the oral bioavailablity of a series of 
2,5-bis(4-amidinophenyl)furan derivatives is a very 
promising approach
6-9
 that proved also useful for the CNS 
delivery of the diamidine antitrypanosomal agents DB844 
and DB289.
10-12
  
 Encouraged by this data, we considered the preparation 
of 1-alkoxy-2-aminoimidazoline derivatives that could 
work as potential prodrugs for the 2-aminoimidazoline 
group. Since our lead compounds (Chart 1) are easily 
   2 
accessible via their Boc-protected precursors, obtained by 
reaction between primary diamines and N,N’-bis(tert-
butoxycarbonyl)imidazoline-2-thione/HgCl2/Et3N,
13
 we 
were especially interested in a methodology using the same 
commercially available aromatic amines as starting 
materials. However, and contrary to N-
hydroxyguanidines,
14-16
 only a few procedures for the 
preparation of 1-hydroxy-2-aminoimidazolines and their O-
alkyl derivatives could be found, mainly in the patent 
literature where no yields were reported (Equation 1).
17-22
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Results and discussion 
 None of the methods mentioned above resulted 
convenient for the preparation of our target compounds due 
in part to the difficulty to get the N-alkoxyethylenediamine 
precursors (2) easily and in high yields. For instance, 4a 
was obtained satisfactorily from 2-
bromoethylphthalimide/O-benzylhydroxylamine following 
the reported procedure,
20
 but several attempts to synthesise 
the corresponding methyl (4b) and ethyl (4c) analogues 
[RONH2.HCl (2 equiv)/ DIPEA (2 equiv)/ CH3CN, 80 ºC, 
2 days] resulted only in low yields (20%) of the product 
together with a major dione by-product (4d and 4e, 
respectively). This result is probably due to the unstability 
of 4b and 4c in the basic reaction medium, resulting in the 
intramolecular nucleophilic attack of the N-alkoxyamine at 
the phthalimide carbonyl group.
23
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 The fact that this rearrangement was not observed with 
4a is possibly due to steric factors with the bulkier benzyl 
group. The use of a base to deprotonate the hydrochloride 
salt of the alkoxylamine reagent in the reaction medium 
may also favour the rearrangement.
23
 
 We found that protecting the secondary amine with the 
2-nitrobenzenesulfonamide (Ns) group
24,25
 was a very 
convenient way to avoid the problem of rearrangement of 
4a and 4b through intramolecular cyclization. Thus, O-
alkyl-N-nosyl hydroxylamines 5a–8a were prepared easily, 
in good yields, by sulfonylation (NsCl/ pyridine/ CH2Cl2) 
of hydroxylamines 5, 6, 7
26
 and 8, respectively, followed 
by acidic workup and crystallization from acetone/hexane
27
 
(Scheme 1). 
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 The 2-nitrobenzenesulfonamides 5a–8a were alkylated 
at room temperature with 2-bromoethylphthalimide to give 
high yield of the corresponding 2-
nitrobenzenesulfonamides 5b–8b as colorless solids.
28
 In 
most cases, the products were obtained in sufficient purity 
(> 95 % by HPLC) by water-mediated precipitation from 
the reaction mixture.
29
 The phthalimide protecting group 
was removed easily by treatment with an excess of 
hydrazine monohydrate in EtOH affording 5c–8c.
30
 The 
non-optimized overall yield for the three step synthesis of 
the N-alkoxy-N-nosyl-2-aminoethane derivatives was pretty 
satisfying (ca. 60 %).  
 It should be noted that, upon storage as free base, these 
primary amines tend to rearrange to cyclic secondary 
amines (5d–8d) via an intramolecular process. This 
reaction presumably occurs either by direct intramolecular 
aromatic nucleophilic substitution of the nitro group or 
possibly through Smiles rearrangement followed by an 
annulation process with concomitant loss of nitrous 
acid.
31,32
 This drawback can be overcome simply if the 
reagent is stored as its phthalimide precursor 5b–8b and the 
amino group is deprotected immediately before use.  
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 Phenylisothiocyanate was chosen as a model compound 
to test this synthetic approach (Scheme 2). A screening of 
the reaction conditions for the condensation of 5c with 
phenylisothiocyanate showed that 1.5 equiv. of amine 5c 
were necessary whereas the addition of base (DIPEA), 
heating of the reaction or changing the solvent (THF, 
CH3CN, toluene) did not modify significantly the yield of 
the formation of 9. On the contrary, the dropwise addition 
of a dilute solution of the isothiocyanate to the amine was 
critical to avoid the formation of large amounts of 1,3-
diphenylthiourea by-product. 
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We were pleased to verify that there is no need to isolate 
the thiourea intermediate in order to complete this synthetic 
route. Indeed, after checking the complete formation of 9 
by HPLC–MS, the crude reaction mixture was treated with 
PhSH (5 equiv)/ K2CO3 (10 equiv)
33
 following Fukayamas’ 
protocol.
24
 In this way, 9 was converted directly to the 1-
methoxy-2-phenylaminoimidazoline product 11 via 
formation of the amine intermediate 10 (77% for 3 steps). 
This new protocol was validated with the synthesis of the 
target compounds 12–15 (scheme 3) in moderate to high 
yield (42
34
–74%).
35
 It should be noted that in this case, i.e. 
synthesis of symmetric bis-imidazolines, the last step 
required longer reaction time (ca. 3 days) in order to 
complete the cyclization of the amino-thiourea 
intermediate. Alternatively, heating the reaction vessel at 
65 ºC allowed the cyclization to occur in approximately 
4h.
36
 
12: R = Bn (74%)
13: R = Me (48%)
14: R = Et (42%)
15: R= THP (56%)
1) 5c-8c (2.5 equiv), DMF, rt
2) PhSH (10 equiv), K2CO3 (20 equiv)
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 In summary, we have reported a new methodology that 
is very convenient for the synthesis of 1-alkoxy-2-
aminoimidazoline derivatives starting from N-alkoxy-N-(2-
aminoethyl)-2-nitrobenzenesulfonamides that are easily 
obtained in high yield in three steps from commercial 
hydroxylamines. This method proved practical for the one 
pot synthesis of mono- and bis(1-alkoxy-2-
arylamino)imidazolines in good yield (42–77% total yield 
from the starting isothiocyanate). 
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solid (148 mg, 74%); mp > 93 ºC; δH (300 MHz, CDCl3) 
7.47–7.30 (10H, m, Ar), 7.09 (4H, d, J 8.5 Hz, Ar), 6.92 (4H, 
d, J 8.5, Ar), 6.57 (1H, s, NH), 5.29 (2H, br s, NH), 4.94 (4H, 
s, OCH2), 3.45 (4H, br t, J 7.2), 3.25 (4H, br t, J 7.2); δC(75 
MHz, CDCl3) 159.5 (C=N), 140.3 (C), 136.3 (C), 129.6 (CH), 
   5
128.8 (CH), 128.7 (CH), 122.3 (CH), 118.2 (CH), 78.2 
(OCH2), 52.7 (NCH2), 45.8 (NCH2); m/z 548.52 (M+H); 
HPLC: 93%; Found: C, 65.21; H, 6.38; N, 
16.21.C32H33N7O2·2.3 H2O requires C, 65.18; H, 6.44; N, 
16.63. Compound 13: brownish amorphous solid (174 mg, 
48%); mp 103–105 ºC; δH (300 MHz, CD3OD) 7.01 (4H, d, J 
8.7 Hz, Ar), 6.88 (4H, d, J 8.7, Ar), 3.67 (6H, s, OCH3), 3.32 
(4H, m), 3.2 (4H, M); δC(75 MHz, CD3OD) 160.4 (C=N), 
140.5 (C), 135.3 (C), 122.5 (CH), 117.9 (CH), 62.2 (CH3), 
51.1 (CH2), 43.7 (CH2); m/z 396.4 (M+H); HPLC: 98%. 
Compound 14: brownish solid (83 mg, 42%); mp 78–82 ºC; 
δH (300 MHz, DMSO–d6) 7.99 (1H, br s, NH), 7.34 (4H, d, J 
8.7 Hz, Ar), 6.96 (4H, d, J 8.7, Ar), 3.98 (4H, q, J 7), 3.5–3.4 
(8H, m), 1.23 (6H, t, J 7); δC(75 MHz, DMSO–d6) 159.1 
(C=N), 139.8 (C), 133.0 (C), 122.3 (CH), 117.2 (CH), 70.4 
(CH2), 52.0 (CH2), 44.5 (br, CH2), 13.8 (CH3); m/z 424 
(M+H); HPLC: 97%. Compound 15: brownish amorphous 
solid (47 mg, 56%); mp > 80 ºC; δH (300 MHz, CDCl3) 7.33 
(4H, d, J 8.7 Hz, Ar), 6.94 (4H, d, J 8.7, Ar), 5.55 (1H, br s, 
NH), 5.28 (2H, s, NH), 4.86 (2H, br m, OCH), 4.13 (2H, m, 
OCH2), 3.75–3.55 (8H, m, NCH2CH2N+OCH2), 3.30 (2H, d, 
J 8.3, CH2N), 1.89–1.81 (4H, m), 1.57 (8H, br m); δC(75 
MHz, CDCl3) 159.6 (C=N), 138.6 (C), 133.6 (C), 119.8 (CH), 
118.4 (CH), 104.6 (OCH), 65.8 (OCH2), 53.9 (NCH2), 49.2 
(NCH2), 29.3 (CH2), 24.8 (CH2), 21.4 (CH2); m/z 536.51 
(M+H); HPLC: 93%. 
36. In this case, the reaction should be carefully monitored (i.e., 
avoid high temperature and prolonged reaction times) to 
avoid the formation of dealkylation products. 
 
 
